Basic Information
DEXMEDETOMIDINE FRESENIUS CONCENTRATE FOR SOLUTION FOR INFUSION 100MCG/ML
INJECTION
Regulatory Information
SIN16908P
December 12, 2023
Prescription Only
Therapeutic
INTRAVENOUS
January 24, 2024
June 3, 2025
XN05CM18
Company Information
Active Ingredients
Strength: 100mcg/ml
Detailed Information
Contraindications
**9 Contraindications** Hypersensitivity to the active substance or to any of the excipients in the formulation. Advanced heart block (grade 2 or 3) unless paced. Uncontrolled hypotension. Acute cerebrovascular conditions.
Indication Information
**7 Indications** **Intensive Care Unit Sedation** Dexmedetomidine is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Dexmedetomidine should be administered by continuous infusion not to exceed 24 hours. Dexmedetomidine has been continuously infused in mechanically ventilated patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue dexmedetomidine prior to extubation. **Procedural Sedation** Dexmedetomidine is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.